treating kids news report medication

Delayed- and Extended-Release Methylphenidate Improve Functional Impairment in Children with ADHD

Reading now: 938

June 11, 2021Treatment with delayed-release and extended-release methylphenidate (DR/ER-MPH) led to clinically meaningful improvements in functional impairment in children with ADHD compared to placebo.

This study, which demonstrated significant improvements in before- and after-school impairments, was published in the Journal of Attention Disorders and funded by Ironshore Pharmaceuticals, maker of Jornay PM, an ER-MPH taken at night.1The data source for this study was a post hoc analysis based on data from a randomized, double-blind, multi-center, placebo-controlled trial of DR/ER-MPH in 161 children with diagnosed ADHD.

The website is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles